Leerink Partners analyst Daina Graybosch maintained a Buy rating on BioNTech SE (BNTX – Research Report) on March 21 and set a price target of $113.00.
Daina Graybosch has given her Buy rating due to a combination of factors related to BioNTech SE’s recent developments in small cell lung cancer (SCLC) treatments. The preliminary outcomes from the European Lung Cancer Congress (ELCC) suggest that the combination of BNT327 with chemotherapy shows promising durability of benefit in both first-line and second-line extensive stage SCLC. Particularly, the 12-month overall survival rate of 73% in first-line SCLC is significantly higher than relevant benchmarks, indicating a potential competitive advantage.
Moreover, the median duration of response in immuno-oncology naïve patients in the second-line setting is notably longer than existing benchmarks, which further supports the potential efficacy of BNT327. Despite some uncertainties regarding the data, such as the extent of censoring, these promising signals contribute to the positive outlook for BioNTech’s stock. Graybosch’s rating reflects confidence in the potential of BNT327 to impact the SCLC treatment landscape positively.
In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $139.00 price target.